Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Leases: 2019-2025

Historic Current Leases for Cytokinetics (CYTK) over the last 7 years, with Sep 2025 value amounting to $20.6 million.

  • Cytokinetics' Current Leases rose 9.50% to $20.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year increase of 9.50%. This contributed to the annual value of $19.0 million for FY2024, which is 6.08% up from last year.
  • Cytokinetics' Current Leases amounted to $20.6 million in Q3 2025, which was up 5.42% from $19.6 million recorded in Q2 2025.
  • Cytokinetics' 5-year Current Leases high stood at $20.6 million for Q3 2025, and its period low was $5.3 million during Q1 2021.
  • Over the past 3 years, Cytokinetics' median Current Leases value was $18.5 million (recorded in 2024), while the average stood at $18.1 million.
  • As far as peak fluctuations go, Cytokinetics' Current Leases spiked by 433.68% in 2021, and later fell by 13.68% in 2022.
  • Over the past 5 years, Cytokinetics' Current Leases (Quarterly) stood at $14.9 million in 2021, then fell by 13.68% to $12.8 million in 2022, then spiked by 39.46% to $17.9 million in 2023, then climbed by 6.08% to $19.0 million in 2024, then increased by 9.50% to $20.6 million in 2025.
  • Its last three reported values are $20.6 million in Q3 2025, $19.6 million for Q2 2025, and $19.6 million during Q1 2025.